Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin and T2T Strategy in Psoriatic Arthritis Atherosclerosis
NCT04176978Withdrawn
- Sponsor
- The Chinese University of Hong Kong
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of rosuvastatin in atherosclerosis (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Change in Carotid Intima-Media Thickness at 12 months. Planned start Apr 2021; status: withdrawn.
02
Drugs
rosuvastatin
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT04176978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176978.